BlackRock
ANRO icon

BlackRock’s Alto Neuroscience ANRO Stock Holding History

BlackRock’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56M Buy
2,121,009
+1,454,821
+218% +$33.6M ﹤0.01% 2614
2026
Q1 		$15M Buy
666,188
+58,314
+10% +$1.08M ﹤0.01% 3251
2025
Q4 		$10.8M Buy
607,874
+239,995
+65% +$3.02M ﹤0.01% 3423
2025
Q3 		$1.48M Sell
367,879
-193,969
-35% -$643K ﹤0.01% 4187
2025
Q2 		$1.24M Sell
561,848
-897,328
-61% -$2.14M ﹤0.01% 4190
2025
Q1 		$3.15M Sell
1,459,176
-20,838
-1% -$74.6K ﹤0.01% 3836
2024
Q4 		$6.26M Buy
1,480,014
+34,280
+2% +$214K ﹤0.01% 3634
2024
Q3 		$16.5M Buy
1,445,734
+874,810
+153% +$10.7M ﹤0.01% 3161
2024
Q2 		$6.1M Buy
570,924
+429,356
+303% +$5.59M ﹤0.01% 3617
2024
Q1 		$2.17M Buy
+141,568
New +$2.22M ﹤0.01% 3975

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock's ANRO Position: Q2 2026 in Review

BlackRock increased its Alto Neuroscience (ANRO) stake by 218% in Q2 2026, buying an estimated $33.6M and bringing the position to 2,121,009 shares worth $56M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

BlackRock first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • BlackRock held 2,121,009 shares of Alto Neuroscience worth $56M as of Q2 2026.
  • BlackRock bought 1,454,821 Alto Neuroscience shares in Q2 2026, an estimated $33.6M.
  • Alto Neuroscience made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2614 holding.
  • BlackRock first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.